Viridian Therapeutics, Inc. (LON:0K1R)
16.32
+0.23 (1.43%)
At close: Aug 11, 2025
G1 Therapeutics Revenue
Viridian Therapeutics had revenue of $75.00K USD in the quarter ending June 30, 2025, with 4.17% growth. This brings the company's revenue in the last twelve months to $305.00K, up 5.90% year-over-year. In the year 2024, Viridian Therapeutics had annual revenue of $302.00K, down -3.82%.
Revenue (ttm)
$305.00K
Revenue Growth
+5.90%
P/S Ratio
4,877.43
Revenue / Employee
$2.13K
Employees
143
Market Cap
1.09B
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 302.00K | -12.00K | -3.82% |
Dec 31, 2023 | 314.00K | -1.46M | -82.28% |
Dec 31, 2022 | 1.77M | -1.19M | -40.20% |
Dec 31, 2021 | 2.96M | 1.91M | 182.19% |
Dec 31, 2020 | 1.05M | -3.41M | -76.46% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 41.24B |
GSK plc | 31.63B |
Haleon | 11.02B |
Smith & Nephew | 4.33B |
ConvaTec Group | 1.72B |
Hikma Pharmaceuticals | 2.35B |
Oxford Nanopore Technologies | 183.19M |
HUTCHMED (China) | 439.54M |
Viridian Therapeutics News
- 7 days ago - Viridian (VRDN) Q2 Net Loss Widens 55% - The Motley Fool
- 7 days ago - Viridian Therapeutics GAAP EPS of -$1.00 beats by $0.03, revenue of $0.08M beats by $0.03M - Seeking Alpha
- 7 days ago - Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2025 Financial Results - Business Wire
- 9 days ago - Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 14 days ago - Viridian Therapeutics Announces Collaboration and License Agreement with Kissei Pharmaceutical to Develop and Commercialize Veligrotug and VRDN-003 in Japan with an Upfront Payment of $70 Million and up to $315 Million in Milestone Payments - Business Wire
- 5 weeks ago - Viridian Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 2 months ago - Viridian Therapeutics: The Song Remains The Same - Seeking Alpha
- 2 months ago - Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire